公开(公告)号：US20210332327A1

公开(公告)日：2021-10-28

申请号：US17371436

申请日：2021-07-09

Applicant: PROGENA INC.

Inventor： Alexander FESKOV ,  Ievgeniia ZHYLKOVA ,  Stanislav ZHILKOV ,  Irina FESKOVA ,  Vladislav FESKOV

IPC: C12N5/0783 ,  A61K38/24 ,  A61K35/14 ,  C12N5/078 ,  A61K35/12

Abstract: A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.

公开(公告)号：US20240268863A1

公开(公告)日：2024-08-15

申请号：US18604611

申请日：2024-03-14

Applicant: PROGENA INC.

Inventor： Alexander FESKOV ,  Irina FESKOVA ,  Ievgeniia ZHYLKOVA ,  Stanislav ZHILKOV

IPC: A61B17/435 ,  A61D19/00 ,  A61D19/04 ,  A61K35/12 ,  A61K35/14 ,  C12N5/078

CPC classification number: A61B17/435 ,  A61D19/00 ,  A61D19/04 ,  A61K35/14 ,  C12N5/0634 ,  A61K2035/124 ,  C12N2501/31

Abstract: Disclosed is a method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, an preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.

公开(公告)号：US20180057792A1

公开(公告)日：2018-03-01

申请号：US15688385

申请日：2017-08-28

Applicant: Progena Inc.

Inventor： Alexander FESKOV ,  Ievgeniia ZHYLKOVA ,  Stanislav ZHILKOV ,  Irina FESKOVA ,  Vladislav FESKOV

IPC: C12N5/0783 ,  A61K39/00 ,  A61K38/24

CPC classification number: C12N5/0636 ,  A61K35/14 ,  A61K38/24 ,  A61K39/0011 ,  A61K2035/124 ,  C12N5/0634 ,  C12N2502/11 ,  G01N2333/59

Abstract: A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.